Barclays Maintains Overweight on Dr Reddy's Laboratories, Raises Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Balaji Prasad has maintained an Overweight rating on Dr Reddy's Laboratories (NYSE:RDY) and increased the price target from $75 to $80.
January 29, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has reaffirmed an Overweight rating on Dr Reddy's Laboratories and raised the price target from $75 to $80, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst like Barclays usually signals a strong conviction in the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100